Uncategorized

The promise of a botanical approach to autism

Published

on

DDW Editor Reece Armstrong speaks to Joel Stanley, CEO of Ajna BioSciences, about the challenges of developing therapies for autism and why a multi-compound approach may be key to treating symptoms. 

RA: What are the challenges of discovering and developing effective therapies for autism?
 

JS: Autism is an incredibly broad spectrum, which makes it fundamentally different from developing therapies for diseases with a clearly defined biological mechanism, such as a specific gene mutation or deficiency. In many conditions, researchers know exactly what is causing the disease and can design therapies around a singular target. With autism, we still know relatively little about why one person develops an autism diagnosis versus another. 

That complexity is why current FDA-approved therapies, along with our AJA001, focus narrowly on irritability associated with autism rather than attempting to treat autism itself. In clinical development, that becomes important because you have to clearly define the endpoints you’re trying to improve – anxiety, aggression, irritability, or self-injurious behaviour, for example. 

With AJA001, we’re approaching those symptoms differently than conventional pharmaceuticals. Rather than targeting a single receptor or singular neurological pathway, we’re studying a multi-compound, plant-derived therapy designed to support broader neurological balance and overall well-being while reducing irritability associated with autism spectrum disorder. 

The encouraging part is that, while autism itself is complex, we do have validated clinical metrics that allow us to observe meaningful outcomes in patients – whether a therapy is reducing anxiety, aggression, or irritability and improving day-to-day functioning. 

RA: Why does a multi-compound approach potentially offer a better approach to treating autism compared to traditional pharma approaches?
 

JS: Today, the only two FDA-approved drugs for irritability associated with autism are atypical antipsychotics – single-compound drugs originally developed for conditions like schizophrenia. Conventional pharmaceuticals are typically designed around a single molecule that targets a single receptor or a single mechanism of action. 

A botanical, multi-compound therapy works very differently. 

With a full-spectrum cannabinoid therapy, you may have multiple active compounds working synergistically together. Those compounds can potentially improve each other’s efficacy, mitigate side effects, and simultaneously influence multiple neurological systems. 

In the case of a full-spectrum cannabinoid therapy drug, we know the therapy engages cannabinoid receptors like CB1 and CB2, but research also points to activity involving serotonin receptors, GABA systems, and other neurological pathways. That broader mechanism of action may allow for a more balanced therapeutic effect. 

The current antipsychotic options can reduce severe agitation or self-injurious behaviour, but they often do so by heavily suppressing mood and consciousness. Families frequently describe seeing diminished personality, cognition, or emotional engagement in their loved ones after starting those medications. 

By contrast, with full-spectrum cannabinoid therapies, we’ve seen reports suggesting improved cognition, improved engagement, and reduced irritability without that same level of neurological suppression. The mechanism, safety profile, and patient experience are fundamentally different. 

RA: Why do cannabinoids represent a promising approach to autism treatment?
 

JS: There are multiple reasons cannabinoids are promising in autism research. 

First, there is already a substantial amount of real-world observational data from families who have used cannabinoid-based products for children with autism. Through Charlotte’s Web and broader industry experience, we’ve seen thousands of patients use similar full-spectrum cannabinoid formulations with encouraging reports around behaviour, anxiety, and irritability – importantly, without major safety concerns emerging at scale. 

Second, emerging research suggests the endocannabinoid system itself may play a role in autism. 

Some studies have found that individuals with autism commonly express lower levels of endocannabinoids such as anandamide – sometimes referred to as the “bliss molecule.” Anandamide was named by pioneering cannabinoid researcher Raphael Mechoulam after the Sanskrit word ananda, meaning bliss. 

CBD and small amounts of THC – like those included in AJA001 – may help upregulate naturally occurring endocannabinoids like anandamide. Researchers believe that this may contribute to improvements in mood, anxiety, and irritability. 

Beyond that, cannabinoids appear to act across multiple neurological systems. CBD alone has demonstrated activity involving serotonin receptors, while additional cannabinoids such as CBC and CBG may contribute their own therapeutic effects. That multi-pathway activity is one reason cannabinoid therapies may offer a more comprehensive neurological approach than single-target drugs. 

RA: Why has the pharma industry struggled to make much progress into treatments for autism?  

 

JS: The reality is that the currently approved drugs for irritability associated with autism were not originally developed for autism at all. They were developed as antipsychotics for severe psychiatric conditions and later adapted because they could suppress aggressive or highly agitated behaviours. 

That highlights the larger challenge: we still do not fully understand the root biological causes of autism. 

Because autism is such a broad spectrum, it’s unlikely there is one singular cause or one universal therapeutic target. As genomic research advances, we may eventually see more targeted therapies emerge for specific subsets of autism, potentially including gene-based approaches. But that is still likely decades away. 

In the meantime, there remains a major unmet need for therapies that can improve some of the most difficult symptoms associated with autism without introducing severe side effects. 

That’s where we believe cannabinoid-based therapies may play an important role – offering symptom improvement through a mechanism that appears significantly more tolerable than existing antipsychotic approaches. 

RA: What are the current neurological tradeoffs offered by current antipsychotics? 

JS: Current antipsychotics used in autism can be effective in severe cases, particularly when a patient is experiencing dangerous aggression, self-injurious behaviour, or extreme irritability. But the tradeoffs can be substantial. 

These drugs work in part by suppressing neurological activity, including serotonin-related pathways, which can heavily blunt mood and emotional responsiveness. While that suppression may reduce severe agitation, families often describe feeling as though they temporarily “lose” aspects of their loved one’s personality or consciousness. 

Instead of improving mood, the effect can sometimes feel more like emotional suppression or sedation. 

In addition to neurological tradeoffs, these medications also carry significant physical side effects, including severe weight gain and elevated diabetes risk. 

For many families, the challenge is that these remain the only FDA-approved treatment options available today. 

RA: Has real-world data been important when examining the possible benefits of cannabis into autism treatments?  

 

JS: Absolutely. Real-world data has been incredibly important in helping shape cannabinoid research in autism. 

As pioneers in the CBD industry through Charlotte’s Web, we worked closely with families and organisations like Realm of Caring to collect meaningful observational data over many years. Early partnerships with Johns Hopkins University helped contribute to what is now considered one of the world’s largest cannabis research registries. 

Because Charlotte’s Web products are so widely used, a substantial amount of registry data involved patients already using those cannabinoid therapies in real-world settings. 

That dataset has shown statistically significant improvements in areas like anxiety and depression among individuals with autism over long periods of time and across large patient populations. 

One advantage botanical therapies can have is that they often enter formal clinical development with years of observational and safety data already available – something brand-new chemical entities typically do not have. That large body of real-world evidence helps de-risk later-stage clinical trials and provides important direction for future research. This is a major advantage of botanical drugs – that their source materials frequently come with extensive historical and modern safety data. Many botanicals have been used by humans for hundreds or even thousands of years, and some already possess FDA GRAS (Generally Recognized as Safe) status, supported by decades of documented use and, in certain cases, established toxicology data. 

RA: You’re looking to advance AJA001 into Phase II clinical trials. What data are you hoping to see come from this trial? 

JS: The primary goal of the Phase II trial is not only to continue evaluating efficacy signals, which we anticipate seeing, but also to better understand the dose-response curve. 

That dosing data becomes critically important because it helps shape the design of the eventual pivotal Phase III trial required by the FDA. 

So while we certainly expect to see strong efficacy signals around irritability and behavioural improvement, Phase II is also heavily focused on fine-tuning dosing parameters, optimising treatment response, and ensuring the therapy is appropriately positioned for larger-scale studies. 

RA: What’s the company’s remaining plans for 2026? 

JS: Ajna anticipates getting one – possibly two – more investigational new drug applications on file this year. Our next drug in the pipeline will move into Phase I, and we expect the drugs behind it to advance into clinical phases as well. Beyond the AJA001 autism programme, all of our work is about advancing the next drugs in our pipeline through their IND applications and into Phase I and Phase II. 

The broader pipeline includes both cannabinoid and psychedelic-based therapies: 

  • AJA002 is a full-spectrum psilocybin formulation targeting generalised anxiety disorder, which the company views as a potential alternative to traditional antidepressants. 
  • AJA002.5 is a psychedelic-assisted therapy programme built from the same core genetics and is being designed as a direct-to-Phase II programme. 
  • AJA003 is a higher-THC cannabinoid formulation targeting PTSD, another area with limited approved treatment options. 
  • AJA004 is a novel, naturally derived psychedelic therapy intended for psychedelic-assisted treatment settings. 

 

Biography 

Joel Stanley, former CEO and Chairman of Charlotte’s WebTM and now a board member of DeFloria, leads AJNA BioSciences in developing next-generation botanical therapeutics. As one of the eldest of the Stanley Brothers – credited with pioneering Charlotte’s WebTM CBD products and featured in outlets such as CNN, Forbes, The New York Times, and The Washington Post.  

 

From DDW Volume 27 – Issue 3, Summer 2026 – Read the digital issue here

 

The post The promise of a botanical approach to autism appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version